Wilson Sonsini Goodrich & Rosati and Cooley advised Kura Oncology. Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision...
You must be a Standard 1 Year member to access this content.
Leerink Partners is serving as exclusive financial advisor to Tectonic and Cooley LLP is serving as legal counsel to Tectonic. Leerink Partners and TD Cowen are...
You must be a Standard 1 Year member to access this content.
Cooley advised SystImmune on the transaction. SystImmune announced its exclusive license and collaboration agreement with Bristol Myers Squibb (NYSE: BMY) for SystImmune’s BL-B01D1. Under the terms of...
You must be a Standard 1 Year member to access this content.
Cooley advised Seven and Eight Biopharmaceuticals on the deal. Seven and Eight Biopharmaceuticals Inc. announced that it has signed an exclusive licensing agreement with Eikon Therapeutics....
You must be a Standard 1 Year member to access this content.
Cooley advised Impact Therapeutics on the deal. Impact Therapeutics and Eikon Therapeutics announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors...
You must be a Standard 1 Year member to access this content.
Cooley advised Zion Pharma Limited on the deal. Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced the acquisition of its...
You must be a Standard 1 Year member to access this content.
Gibson Dunn acted as legal advisor to RTW, and Cooley acted as legal advisor to Milestone. Milestone Pharmaceuticals Inc. announced that it has entered into a...
You must be a Standard 1 Year member to access this content.
Cooley advised Tmunity on the deal. Tmunity, a clinical-stage biotechnology company, announced its agreement to sell to Kite, a global biopharmaceutical company. The acquisition will provide...
You must be a Standard 1 Year member to access this content.
